Novo Nordisk has received European approval for a new indication of its drug, Ozempic. The European Medicines Agency (EMA) ...

In a new study, researchers evaluated the treatment effects of BI655064, an anti-CD40 monoclonal antibody, as an add-on ...

A new treatment option for patients with uncontrollable high blood pressure is now available at Willis Knighton Health.

Alpha blocker use in females with voiding difficulties and CKD linked to risk of fractures suggests a study published in the ...

Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...

The go-to pill if you have a headache or are feeling under the weather could cause serious damage if they're taken too often ...

Older people who repeatedly took the common painkiller had an increased risk of conditions ranging from heart failure to ...

significantly reduces the risk of progression in chronic kidney disease and cardiovascular mortality in patients with type 2 diabetes. The label expansion could enhance Novo Nordisk’s market ...